




Cervix

→ HPV pathogenesis:

Pathogenic strains - HPV 16, 18, 31, 33, 45
(high risk strains)

→ Non enveloped, double stranded DNA virus

Protective factors

- Intrauterine devices
- Circumcision in men lowers incidence of HPV in men and their female partners.

Basal cell of epidermis

Integration of viral genome into host genome.

2 oncoproteins

E6

↓
P53

inactivation

E7

↓
PRB

inactivation

Environmental factors

(+)

Smoking / alcohol

Genomic instability

(+)


Coinfection with other STDs

↓
HPV associated SCC

→ HPV prevention

Primary prevention

- Prevention before disease occurrence.
- HPV vaccination



Vaccination schedule: - By CDC for Gardasil-9 (By Merck)


A two-dose series (0, 6-12 months) for most persons who initiate vaccination at ages 9 through 14 years.

A three-dose series (0, 1-2, 6 months) for persons who initiate vaccination at ages 15 through 45 years, and for immunocompromised persons.

Indian vaccine
CERVEVAC - quadrivalent
against 6, 11, 16, 18.
By Serum Institute


Secondary prevention

- For early detection & treatment



more sensitive
No observational bias in CIN lesions.

Current screening guidelines by VSPSTF 2018



No screening for > 65 years if past 20 years reports normal.

Woman > 65 years without any prior screening → Pap smear + HPV cotesting.

Post hysterectomy & No Hb CIN 2 or greater

→ No screening recommended.

→ Pathology - pre-invasive - on Pap smear

- Bethesda system
- CIN system
- Papanicolaou system

1) * Specimen type

- Conventional Pap
 - smeared directly on slide
- liquid based cytology
 - Cells suspended in bottle / preservative & sent to lab.
 - Thin prep Pap slides.

2) Specimen adequacy:

unsatisfactory

Satisfactory

- min Squamous cellularity
 - at least 5000 Squamous cells in liquid prep
 - at least 8000 - 12000 cells in conventional prep.
- Endocervical / Transformation zone
 - at least 10 cells in single / clusters.

3) Reporting

* N/Cm - Negative for Intraepithelial lesion or Malignancy.
Epithelial abnormalities

Squamous

Adeno (endocervix)

→ ASCUS - Atypical Squamous Cells of unknown significance

- mc Pap smear report
- 9.1% of Pap smears.
- ↑ N/C ratio

→ ASC-H - Atypical Squamous cells
cannot exclude high grade lesion

→ LSIL - low grade Squamous Intraepithelial lesion

- includes CIN-1 → abnormalities upto lower 1/3rd epithelium.

→ HSIL - High grade Squamous intraepithelial lesion

- includes CIN-2 - lower + middle 1/3rd
- ← CIN-3 - lower + middle + upper 1/3rd epithelium.

→ AGC - Atypical Glandular cells

↓
NOS AIS Adeno CA.
Adeno carcinoma in situ

↓
several benign mimics

- Reactive glandular atypia
- Endometriosis.

→ Endocervical adenocarcinoma classification:


TABLE 48.3

International Endocervical Adenocarcinoma Criteria and Classification (2019)

Main Categories	Morphologic Subcategories (Optional)	World Health Organization
1. HPV-related endocervical adenocarcinoma	HPV adenocarcinoma, usual type	1. Usual type adenocarcinoma
	HPV adenocarcinoma, villoglandular type	2. Villoglandular adenocarcinoma
	HPV adenocarcinoma, mucinous NOS type	3. Mucinous adenocarcinoma NOS
	HPV adenocarcinoma, mucinous intestinal type	4. Mucinous adenocarcinoma, intestinal type
	HPV adenocarcinoma, signet-ring cell type	5. Mucinous adenocarcinoma, signet ring cell
	HPV adenocarcinoma, stratified mucin-producing type	
2. Non-HPV adenocarcinoma, gastric type	- mc in Southeast Asian women	6. Mucinous adenocarcinoma, gastric type
3. Non-HPV adenocarcinoma, endometrioid type	- from Endometriosis	7. Endometrioid carcinoma
4. Non-HPV adenocarcinoma, clear cell type	- diethylstilbestrol exposure	8. Clear cell carcinoma
5. Non-HPV adenocarcinoma, mesonephric type	- very rare	9. Mesonephric carcinoma
6. Non-HPV adenocarcinoma, serous type		10. Serous carcinoma
7. Invasive adenocarcinoma, NOS		11. Invasive adenocarcinoma, NOS

HPV, human papillomavirus; NOS, not otherwise specified.


→ Management of abnormal screening results: → ASCCP Guidelines




Columnar epithelium
Squamous epithelium.

Transformation zone (TZ) - Area between old & new squamocolumnal junction.
- prone to develop malignancy
- Pap test taken from TZ.


★ Co-testing vs Reflex Testing




★ Management of abnormal HPV testing



* Abnormal Pap smear test



* management of abnormal colposcopy Bx:



Risk of progression to invasive malignancy

CIN-I - 1%.
CIN-II - 5%.
CIN-III - 10-12%.


Hysterectomy directly

Indications → Adeno in situ (AIS)

→ CIN 3 in older women

→ women who are unable to follow up.

* management of abnormal LLETZ biopsy report:



* complications of excisional procedures:

- Hemorrhage
- Cervical stenosis
- Cervical incompetence & repeated miscarriage

↓
Procedure to be combined with cervical cerclage.